Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Transgenic sickle mice have vascular inflammation

Open access
Belcher, John D., Bryant, Christopher J., Nguyen, Julia, Bowlin, Paul R., Kielbik, Miroslaw C., Bischof, John C., Hebbel, Robert P., Vercellotti, Gregory M.·2003·Blood

Abstract

Inflammation may play an essential role in vaso-occlusion in sickle cell disease. Sickle patients have high white counts and elevated levels of serum C-reactive protein (CRP), cytokines, and adhesion molecules. In addition, circulating endothelial cells, leukocytes, and platelets are activated. We examined 4 transgenic mouse models expressing human α- and sickle β-globin genes to determine if they mimic the inflammatory response seen in patients. These mouse models are designated NY-S, Berk-SAntilles, NY-S/SAntilles (NY-S × Berk-SAntilles), and Berk-S. The mean white counts were elevated 1.4- to 2.1-fold (P ≤ .01) in the Berk-SAntilles, NY-S/SAntilles, and Berk-S mice, but not in the NY-S mice compared with controls. Serum amyloid P-component (SAP), an acute-phase response protein with 60% to 70% sequence homology to CRP, was elevated 8.5- to 12.1-fold (P ≤ .001) in transgenic sickle mice. Similarly, serum interleukin-6 (IL-6) was elevated 1.6- to 1.9-fold (P ≤ .05). Western blots, confirming immunohistochemical staining, showed vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), and platelet-endothelial cell adhesion molecule (PECAM) were up-regulated 3- to 5-fold (P ≤ .05) in the lungs of sickle mice. Ribonuclease protection assays (RPAs) demonstrated VCAM mRNA also was elevated in sickle mice 1.2- to 1.4-fold (P ≤ .01). Nuclear factor κB (NF-κB), a transcription factor critical for the inflammatory response, was elevated 1.9-fold (P ≤ .006) in NY-S sickle mouse lungs. We conclude that transgenic sickle mice are good models to study vascular inflammation and the potential benefit of anti-inflammatory therapies to prevent vaso-occlusion in sickle cell disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2002-10-3313

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 72

  1. Embury, 1994, Pathogenesis of vasoocclusion., Sickle Cell Disease: Basic Principles and Clinical Practice., 21, 311
  2. Kaul, 2000, Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice., J Clin Invest., 106, 411, 10.1172/JCI9225 · DOI · Paper page
  3. Turhan, 2002, Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm., Proc Natl Acad Sci U S A., 99, 3047, 10.1073/pnas.052522799 · DOI · Paper page
  4. Buchanan, 1983, Recurrent cerebral ischemia during hypertransfusion therapy in sickle cell anemia., J Pediatr., 103, 921, 10.1016/S0022-3476(83)80716-1 · DOI
  5. Awogu, 2000, Leucocyte counts in children with sickle cell anaemia usefulness of stable state values during infections., West Afr J Med., 19, 55
  6. Castro, 1994, The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease., Blood., 84, 643, 10.1182/blood.V84.2.643.643 · DOI · Paper page
  7. Hedo, 1993, Acute phase reactants and severity of homozygous sickle cell disease., J Intern Med., 233, 467, 10.1111/j.1365-2796.1993.tb01000.x · doi:10.1111/j.1365-2796.1993.tb01000.x
  8. Singhal, 1993, Is there an acute-phase response in steady-state sickle cell disease?, Lancet., 341, 651, 10.1016/0140-6736(93)90418-G · doi:10.1016/0140-6736(93)90418-g
  9. Stuart, 1994, Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease., J Clin Pathol., 47, 166, 10.1136/jcp.47.2.166 · DOI
  10. Belcher, 2000, Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion., Blood., 96, 2451, 10.1182/blood.V96.7.2451 · DOI · Paper page
  11. Francis, 1992, Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease., J Natl Med Assoc., 84, 611
  12. Malave, 1993, Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease., Acta Haematol., 90, 172, 10.1159/000204452 · DOI
  13. Croizat, 1994, Circulating cytokines in sickle cell patients during steady state., Br J Haematol., 87, 592, 10.1111/j.1365-2141.1994.tb08318.x · DOI
  14. Kuvibidila, 1997, Tumor necrosis factor alpha in children with sickle cell disease in stable condition., J Natl Med Assoc., 89, 609
  15. Hofstra, 1996, Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst., Blood., 87, 4440, 10.1182/blood.V87.10.4440.bloodjournal87104440 · DOI
  16. Fadlon, 1998, Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64., Blood., 91, 266, 10.1182/blood.V91.1.266 · DOI · Paper page
  17. Lard, 1999, Neutrophil activation in sickle cell disease., J Leukoc Biol., 66, 411, 10.1002/jlb.66.3.411 · DOI · Paper page
  18. Kenny, 1980, Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism., J Clin Pathol., 33, 622, 10.1136/jcp.33.7.622 · DOI · Paper page
  19. Westwick, 1983, Platelet activation during steady state sickle cell disease., J Med., 14, 17
  20. Beurling-Harbury, 1989, Platelet activation during pain crisis in sickle cell anemia patients., Am J Hematol., 31, 237, 10.1002/ajh.2830310404 · DOI
  21. Papadimitriou, 1993, Study of platelet function in patients with sickle cell anemia during steady state and vaso-occlusive crisis., Acta Haematol., 89, 180, 10.1159/000204519 · doi:10.1159/000204519
  22. Wun, 1997, Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia., J Lab Clin Med., 129, 507, 10.1016/S0022-2143(97)90005-6 · DOI · Paper page
  23. Wun, 1999, Platelet-erythrocyte adhesion in sickle cell disease., J Investig Med., 47, 121
  24. Inwald, 2000, Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia., Br J Haematol., 111, 474, 10.1046/j.1365-2141.2000.02353.x · DOI
  25. Solovey, 1997, Circulating activated endothelial cells in sickle cell anemia., N Engl J Med., 337, 1584, 10.1056/NEJM199711273372203 · DOI · Paper page
  26. Solovey, 1998, Tissue factor expression by endothelial cells in sickle cell anemia., J Clin Invest., 101, 1899, 10.1172/JCI1932 · DOI · Paper page
  27. Duits, 1996, Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis., Clin Immunol Immunopathol., 81, 96, 10.1006/clin.1996.0163 · DOI
  28. Saleh, 1998, Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy., Acta Haematol., 100, 26, 10.1159/000040859 · DOI
  29. Saleh, 1999, Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy., Acta Haematol., 102, 31, 10.1159/000040964 · DOI
  30. Stuart, 1999, Sickle cell acute chest syndrome: pathogenesis and rationale for treatment., Blood., 94, 1555, 10.1182/blood.V94.5.1555 · DOI · Paper page
  31. Fabry, 1992, High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia., Proc Natl Acad Sci U S A., 89, 12155, 10.1073/pnas.89.24.12155 · DOI
  32. Rubin, 1991, Hypoxia-induced in vivo sickling of transgenic mouse red cells., J Clin Invest., 87, 639, 10.1172/JCI115041 · DOI
  33. Fabry, 1995, A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity., Blood., 86, 2419, 10.1182/blood.V86.6.2419.bloodjournal8662419 · DOI
  34. Kaul, 1995, In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse., J Clin Invest., 96, 2845, 10.1172/JCI118355 · DOI
  35. Embury, 1999, In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse., J Clin Invest., 103, 915, 10.1172/JCI5977 · DOI
  36. Osarogiagbon, 2000, Reperfusion injury pathophysiology in sickle transgenic mice., Blood., 96, 314, 10.1182/blood.V96.1.314 · DOI · Paper page
  37. Skow, 1983, A mouse model for beta-thalassemia., Cell., 34, 1043, 10.1016/0092-8674(83)90562-7 · DOI · Paper page
  38. Fabry, 1992, High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences., Proc Natl Acad Sci U S A., 89, 12150, 10.1073/pnas.89.24.12150 · DOI
  39. Burlingame, 1996, The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice., J Immunol., 156, 4783, 10.4049/jimmunol.156.12.4783 · DOI
  40. Deryckere, 1994, A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues., BioTechniques., 16, 405
  41. Brown, 1989, Protein measurement using bicinchoninic acid: elimination of interfering substances., Anal Biochem., 180, 136, 10.1016/0003-2697(89)90101-2 · DOI · Paper page
  42. Pepys, 1977, Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein., Lancet., 1, 1029, 10.1016/S0140-6736(77)91260-0 · DOI · Paper page
  43. Osmand, 1977, Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins)., Proc Natl Acad Sci U S A., 74, 739, 10.1073/pnas.74.2.739 · DOI · Paper page
  44. Siebenlist, 1994, Structure, regulation and function of NF-kappa B., Annu Rev Cell Biol., 10, 405, 10.1146/annurev.cb.10.110194.002201 · DOI · Paper page
  45. Le, 1984, In vitro induction of hepatocyte synthesis of the acute phase reactant mouse serum amyloid P-component by macrophages and IL 1., J Leukoc Biol., 35, 587, 10.1002/jlb.35.6.587 · doi:10.1002/jlb.35.6.587
  46. Hebbel, 1981, Modulation of erythrocyte-endothelial interactions and the vasooclusive severity of sickling disorders., Blood., 58, 947, 10.1182/blood.V58.5.947.bloodjournal585947 · doi:10.1182/blood.v58.5.947.bloodjournal585947
  47. Hebbel, 1985, The adhesive sickle erythrocyte: cause and consequence of abnormal interactions with endothelium, monocytes/macrophages and model membranes., Clin Haematol., 14, 141, 10.1016/S0308-2261(21)00466-5 · DOI
  48. Kaul, 1989, Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications., Proc Natl Acad Sci U S A., 86, 3356, 10.1073/pnas.86.9.3356 · DOI · Paper page
  49. Francis, 1991, Vascular occlusion in sickle cell disease: current concepts and unanswered questions., Blood., 77, 1405, 10.1182/blood.V77.7.1405.1405 · DOI · Paper page
  50. Hebbel, 1994, Sickle cell adherence., 217
  51. Hebbel, 1997, The endothelial biology of sickle cell disease., J Lab Clin Med., 129, 288, 10.1016/S0022-2143(97)90176-1 · DOI
  52. Bernini, 1998, Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease., Blood., 92, 3082, 10.1182/blood.V92.9.3082 · DOI · Paper page
  53. Mahoney, 1983, Monocyte functions in sickle cell disorders., Am J Pediatr Hematol Oncol., 5, 409, 10.1097/00043426-198324000-00016 · DOI
  54. Boghossian, 1991, Abnormal neutrophil adhesion in sickle cell anaemia and crisis: relationship to blood rheology., Br J Haematol., 78, 437, 10.1111/j.1365-2141.1991.tb04461.x · DOI
  55. Mohamed, 1993, Increased in vivo activation of neutrophils and complement in sickle cell disease., Am J Trop Med Hyg., 49, 799, 10.4269/ajtmh.1993.49.799 · DOI
  56. Mollapour, 1998, Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease., Blood., 91, 3423, 10.1182/blood.V91.9.3423 · DOI
  57. Abboud, 1998, Granulocytosis causing sickle-cell crisis., Lancet., 351, 959, 10.1016/S0140-6736(05)60614-9 · DOI
  58. Adler, 2001, Fatal sickle cell crisis after granulocyte colony-stimulating factor administration., Blood., 97, 3313, 10.1182/blood.V97.10.3313 · DOI · Paper page
  59. Grigg, 2001, Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia., Blood., 97, 3998, 10.1182/blood.V97.12.3998 · DOI
  60. Charache, 1992, Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia., Blood., 79, 2555, 10.1182/blood.V79.10.2555.2555 · DOI · Paper page
  61. Platt, 1995, Sickle cell paths converge on hydroxyurea., Nat Med., 1, 307, 10.1038/nm0495-307 · DOI
  62. Charache, 1996, Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia., Medicine (Baltimore, MD)., 75, 300, 10.1097/00005792-199611000-00002 · DOI · Paper page
  63. Howard, 1997, Hydroxyurea in the treatment of sickle-cell anemia., Ann Pharmacother., 31, 1393
  64. Hebbel, 1982, Spontaneous oxygen radical generation by sickle erythrocytes., J Clin Invest., 70, 1253, 10.1172/JCI110724 · DOI · Paper page
  65. Shi, 1999, The role of hydroxyl radical as a messenger in the activation of nuclear transcription factor NF-kappaB., Mol Cell Biochem., 194, 63, 10.1023/A:1006904904514 · DOI
  66. McFaul, 2000, Hemoglobin stimulates the release of proinflammatory cytokines from leukocytes in whole blood., J Lab Clin Med., 135, 263, 10.1067/mlc.2000.105180 · DOI
  67. Hammerman, 1997, Endothelin-1 production during the acute chest syndrome in sickle cell disease., Am J Respir Crit Care Med., 156, 280, 10.1164/ajrccm.156.1.9611085 · DOI
  68. Werdehoff, 1998, Elevated plasma endothelin-1 levels in sickle cell anemia: relationships to oxygen saturation and left ventricular hypertrophy., Am J Hematol., 58, 195, 10.1002/(SICI)1096-8652(199807)58:3<195::AID-AJH6>3.0.CO;2-M · doi:10.1002/(sici)1096-8652(199807)58:3<195::aid-ajh6>3.0.co;2-m
  69. Graido-Gonzalez, 1998, Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis., Blood., 92, 2551, 10.1182/blood.V92.7.2551 · DOI · Paper page
  70. Faller, 1999, Endothelial cell responses to hypoxic stress., Clin Exp Pharmacol Physiol., 26, 74, 10.1046/j.1440-1681.1999.02992.x · DOI · Paper page
  71. Phelan, 1995, Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture., J Clin Invest., 96, 1145, 10.1172/JCI118102 · DOI
  72. Zimmerman, 1994, Mechanisms of reperfusion injury., Am J Med Sci., 307, 284, 10.1097/00000441-199404000-00009 · DOI · Paper page

Cited by

See all 242

Metadata

Authors
Belcher, J. D., Bryant, C. J., Nguyen, J., Bowlin, P. R., Kielbik, M. C., Bischof, J. C., Hebbel, R. P., & Vercellotti, G. M.
Venue
Blood
Published
2003-05-15
Volume
101
Issue
10
Pages
3953-3959
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1968642156
Cited by
242
References
6
FWCI
5.53
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transgenic sickle mice have vascular inflammation. https://app.cochat.ai/papers/10.1182/blood-2002-10-3313
The paper
Belcher, J. D., Bryant, C. J., Nguyen, J., Bowlin, P. R., Kielbik, M. C., Bischof, J. C., Hebbel, R. P., & Vercellotti, G. M. (2003). Transgenic sickle mice have vascular inflammation. Blood. https://doi.org/10.1182/blood-2002-10-3313

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.